Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

You mean this study. January 24, 2013 PR. Research by BIDMC combined Kevetrin with sunitinib (marketed as Sutent by Pfizer), on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that “the Kevetrin/sunitinib combination is the first we’ve used in which actual tumor shrinkage is noted.” Seems Lab test conducted alone by Beth Israel.